Drugs / Eleview
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03350217 Comparator | Oct 2017 → Jan 2019 | bleeding disorder, vascular-type, hemorrhagic disease | Indiana University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eleview | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03350217 ↗ |
| Known as | SIC-8000 | “SIC-8000 (Eleview; Aries Pharmaceuticals, La Jolla, Calif) is a commercially available U.S. Food and Drug Administration-approved solution” PMID 31288028 ↗ Jul 2019 |
| Route | Other | “The appropriate solutions will be injected into the submucosal space beneath the lesion(s) to be excised before the lesion(s) is/are removed.” NCT03350217 ↗ |